

Resource Summary Report

Generated by [Kravitz](#) on Sep 10, 2026

Texas A and M University Institute of Biosciences and Technology High Throughput Research and Screening Center Combinatorial Drug Discovery Core Facility

RRID:SCR_022214

Type: Tool

Proper Citation

Texas A and M University Institute of Biosciences and Technology High Throughput Research and Screening Center Combinatorial Drug Discovery Core Facility
(RRID:SCR_022214)

Resource Information

URL: https://vpr.tamu.edu/core_facility/high-throughput-research-and-screening-center/

Proper Citation: Texas A and M University Institute of Biosciences and Technology High Throughput Research and Screening Center Combinatorial Drug Discovery Core Facility
(RRID:SCR_022214)

Description: Core provides industry standard high throughput screening and automated microscopy capabilities to scientists performing drug discovery research. Provides access to automated infrastructure to support phenotypic and biochemical targets. Provides ready access to collections of current FDA approved drugs and clinical candidates exhibiting drug like qualities of acceptable solubility, desirable ADME/toxicology properties and adequate bioavailability. Has collections of mechanistically annotated informer sets that are pathway specific modulators for studying mechanism of action or target identification, collections of natural products and diverse sets of small molecules that can be interrogated for new target discovery. Each project is individually evaluated and team of scientists from CDDP is created to fit specific needs of project from assay design and development through primary, secondary and orthogonal screening.

Abbreviations: CDDP

Synonyms: TAMU - Combinatorial Drug Discovery Program (CDDP), TAMU IBT High Throughput Research and Screening Center CDDP, Texas A&M Health Science Center TAMU - Combinatorial Drug Discovery Program (CDDP), Texas A&M University Houston IBT High Throughput Research and Screening Center CDDP

Resource Type: access service resource, core facility, service resource

Keywords: USEDit, ABRF, standard high throughput screening, automated microscopy, FDA approved drugs collection, clinical candidates, new target discovery

Resource Name: Texas A and M University Institute of Biosciences and Technology High Throughput Research and Screening Center Combinatorial Drug Discovery Core Facility

Resource ID: SCR_022214

Alternate IDs: ABRF_1354

Alternate URLs: <https://coremarketplace.org/?FacilityID=1354>

Record Creation Time: 20220429T050129+0000

Record Last Update: 20260905T133424+0000

Ratings and Alerts

No rating or validation information has been found for Texas A and M University Institute of Biosciences and Technology High Throughput Research and Screening Center Combinatorial Drug Discovery Core Facility.

No alerts have been found for Texas A and M University Institute of Biosciences and Technology High Throughput Research and Screening Center Combinatorial Drug Discovery Core Facility.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [Kravitz](#).

Houl JH, et al. (2026) Role of the ETV5/p38 Signaling Axis in Aggressive Thyroid Cancer Cells. Molecular cancer therapeutics, 25(5), 844.

Li W, et al. (2025) Lasalocid A selectively induces the degradation of MYD88 in lymphomas harboring the MYD88 L265P mutation. Blood, 145(10), 1047.

Ghosh S, et al. (2024) Enhancing efficacy of the MEK inhibitor trametinib with paclitaxel in KRAS-mutated colorectal cancer. Therapeutic advances in medical oncology, 16, 17588359241303302.

Ghosh S, et al. (2024) Enhancing efficacy of the MEK inhibitor trametinib with paclitaxel in KRAS -mutated colorectal cancer. bioRxiv : the preprint server for biology.

Ghosh S, et al. (2023) Vincristine Enhances the Efficacy of MEK Inhibitors in Preclinical Models of KRAS-mutant Colorectal Cancer. *Molecular cancer therapeutics*, 22(8), 962.